Skip to main
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen Inc. demonstrated strong momentum in its business with a year-over-year revenue growth of 23.5% and an increase in active breast resensation programs by 7%, contributing to a significant rise in productivity among high-potential accounts. The company raised its full-year 2025 guidance to at least 19% growth, reflecting a solid outlook bolstered by improvements in insurance coverage for its products, which expanded to over 64% of covered lives. Additionally, industry recognition of nerve allograft as a standard medical practice by professional associations further supports Axogen's market position and growth potential.

Bears say

Axogen Inc's reliance on its flagship product, Avance Nerve Graft, is expected to decline due to the launch of newer products, Axoguard HA+ and Avive+, though uncertainties surrounding the FDA submission pose potential risks to revenue growth. The company's revenue generation from high potential accounts has decreased, which is projected to weigh on overall account growth and market penetration, highlighting vulnerabilities in Axogen's growth strategy. Despite reporting a gross margin of 76.6% surpassing expectations, significant one-time costs related to the anticipated BLA approval and potential label restrictions may further hinder profitability and investor confidence in the firm.

AxoGen (AXGN) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 8 analysts, AxoGen (AXGN) has a Buy consensus rating as of Apr 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.